SUPERNUS PHARMACEUTICALS, INC.

Supernus Pharmaceuticals is celebrating the five-year anniversary of the U.S. FDA approval of Qelbree (viloxazine extended-release capsules) for attention-deficit/hyperactivity disorder (ADHD). Since its initial approval for pediatric ADHD in April 2021 and subsequent approval for adults in April 2022, Qelbree has seen approximately 3 million prescriptions filled, with over 1 million in 2025 alone. The company highlights Qelbree's differentiated approach as the first novel, non-stimulant ADHD medication in over a decade, offering 24-hour exposure and no evidence of abuse potential.

Supernus Pharmaceuticals, Inc. held its Annual Meeting of Stockholders on June 18, 2026. Stockholders elected Frederick M. Hudson and Charles W. Newhall, III as Class I Directors. They also approved, on a non-binding basis, the compensation paid to named executive officers and ratified KPMG LLP as the independent public accounting firm for 2026. Additionally, a proposal to amend the 2021 Equity Incentive Plan to increase available shares was approved.

Supernus Pharmaceuticals announced that its management will participate in two investor conferences in June 2026. The company will attend the 2026 Jefferies Global Healthcare Conference on June 3, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 8, 2026. A live audio webcast of the Jefferies conference will be accessible on the company's website, with archived replays available for 60 days.

Supernus Pharmaceuticals announced it is obligated to pay approximately $33.4 million under its Contingent Value Right (CVR) Agreement. This obligation arose because Milestone 1, as defined in the CVR Agreement, was achieved on March 18, 2026. The company will pay $0.50 per CVR, with funds to be deposited with the Rights Agent within 20 business days of the May 17, 2026 notice date.

Supernus Pharmaceuticals announced that its President and CEO, Jack A. Khattar, will participate in a fireside chat at the Bank of America 2026 Health Care Conference. The presentation is scheduled for May 12, 2026, at 3:40 p.m. PT in Las Vegas, NV. Investors can access a live audio webcast and an archived replay of the event through the company's investor relations website.

Supernus Pharmaceuticals reported a significant increase in total revenues for Q1 2026, reaching $207.7 million, up from $149.8 million in Q1 2025. This growth was primarily driven by new collaboration revenue from ZURZUVAE and increased net product sales for Qelbree and GOCOVRI, alongside new sales from ONAPGO. The company also narrowed its net loss to $2.3 million, or $(0.04) per share, compared to a net loss of $11.8 million, or $(0.21) per share, in the prior year period. The company also resolved ONAPGO supply constraints and recognized a $20.0 million licensing revenue from Shionogi.

Supernus Pharmaceuticals reported strong first quarter 2026 financial results, with total revenues increasing 39% year-over-year to $207.7 million. The combined revenues from its four growth products surged 56% to $149.1 million, driven by strong sales of Qelbree, GOCOVRI, ZURZUVAE, and ONAPGO. The company reiterated its full year 2026 financial guidance and provided updates on its pipeline, including an expected regulatory submission for a second ONAPGO supplier in Q3 2026.

Supernus Pharmaceuticals reported strong first quarter 2026 financial results, with total revenues increasing 39% to $207.7 million. Combined revenues from its four growth products surged 56% to $149.1 million, driven by significant sales increases for Qelbree, GOCOVRI, ZURZUVAE, and the addition of ONAPGO sales. The company also announced an expected Q3 2026 regulatory submission to the FDA for a second supplier for ONAPGO and reiterated its full-year 2026 financial guidance.

Supernus Pharmaceuticals, Inc. announced its 2026 Annual Meeting of Stockholders will be held virtually on June 18, 2026. Stockholders will vote on the election of two directors, the non-binding approval of executive compensation, the ratification of KPMG LLP as independent auditor, and a proposal to increase shares available under the 2021 Equity Incentive Plan. The record date for voting was April 29, 2026.

Supernus Pharmaceuticals, Inc. announced it will report its first quarter 2026 financial and business results after the market closes on Tuesday, May 5, 2026. The company will host a conference call and webcast on the same day at 4:30 p.m. ET to discuss these results. This announcement provides investors with the date to anticipate the company's latest financial performance update.